Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Innoviva | Vintage Vibes

3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

MarketBeat

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Significant updates from the FDA toward the end of 2025 have rallied investor interest in Axsome and Innoviva, two high-potential biotech names for 2026.

MarketBeat

3 Lucrative Biotech Stock Buys for Success

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Safe Biotech Stocks to Buy This Week

Given enhanced healthcare spending, the growing frequency of chronic diseases, government support, and rapid digital transformation, the biotech industry appears to have favorable prospects. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Acorda Therapeutics, Inc. (ACOR) could be ideal additions to your portfolio this week. Read more….

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

Benzinga

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ:INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire differentiated,…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

Benzinga

People

Mor

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Regeneron Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.